IBM's third-quarter results show modest revenue growth and strong free cash flow, but the upcoming separation of Kyndryl and a significant reduction in revenue for November and December present short-term headwinds. The anticipated EPS impact and cautious guidance may weigh on investor sentiment in the near term.

[-1]